Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Inclusion criteria:

* Patients must have a diagnosis of active multiple myeloma
* Patients must have received at least one prior line of therapy and their disease has relapsed..
* Patients must be suitable for treatment with lenalidomide \& dexamethasone.
* Adults ≥ 18 years old
* ECOG Performance Status ≤ 2
* Life expectancy \> 12 weeks
* Patients must have acceptable neutrophil and platelet counts as well as adequate kidney and liver function.
* Able to sign informed consent and to comply with the protocol

Exclusion criteria:

* Primary refractory MM
* Peripheral neuropathy ≥ CTCAE grade 2
* Impaired cardiac function or clinically significant cardiac diseases
* Impairment of GI function or GI disease that may significantly alter the absorption of LBH589
* Patients with diarrhea \> CTCAE grade 1
* Patients using medications that have a relative risk of prolonging the QT interval
* Concomitant use of CYP3A4 inhibitors
* Patients with a history of deep vein thrombosis or thromboembolism within \< 6 months prior to starting study treatment
* Patients who have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
* Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using 2 reliable forms of birth control
* Male patients whose sexual partners are WOCBP and who are unable to use a latex condom during sexual contact (even if they have undergone a vasectomy)
* Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff.

Other protocol defined inclusion/exclusion criteria may apply